June 23 (Reuters) - Cidara Therapeutics Inc CDTX.O:
CIDARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B NAVIGATE TRIAL EVALUATING CD388, A NON-VACCINE PREVENTATIVE OF SEASONAL INFLUENZA
CIDARA THERAPEUTICS INC - STUDY MEETS PRIMARY AND SECONDARY EFFICACY ENDPOINTS
CIDARA THERAPEUTICS INC - CD388 DOSES SHOW 76%, 61%, AND 58% PROTECTION FROM INFLUENZA
CIDARA THERAPEUTICS INC - CD388 WELL-TOLERATED WITH NO SAFETY SIGNALS OBSERVED
Source text: ID:nGNX5vkFJz
Further company coverage: CDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.